68 results
Page 3 of 4
F-3
EX-3.1
muxa1ccj1rft6k
13 Jan 21
Shelf registration (foreign)
1:59pm
6-K
EX-99.1
j3buqqih
13 Nov 20
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome
6:30am
6-K
EX-99.2
i18f52j9epkd95qwtk
8 Sep 20
Innate Pharma Reports First Half 2020 Financial Results and Business Update
6:10am
6-K
EX-99.1
xbfmlkf7n mo0r
8 Sep 20
Innate Pharma Reports First Half 2020 Financial Results and Business Update
6:10am
6-K
EX-99.1
54u5ud6msgm7mrs
24 Jun 20
Current report (foreign)
6:30am
20-F
bs7rx
24 Apr 20
Annual report (foreign)
10:43am
20-F
EX-1.1
bm4r7v b8us5wm14n0e8
24 Apr 20
Annual report (foreign)
10:43am
6-K
EX-99.1
2ny0px78z rdazr6aue
10 Mar 20
Innate Pharma Reports Full Year 2019 Financial Results and Business Update
6:30am
6-K
EX-99.1
eumwx
14 Jan 20
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
6:30am
6-K
EX-99.1
rtk4e5q 51cqmy
9 Jan 20
Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial
6:30am
6-K
EX-99.1
94z9hab
13 Dec 19
Innate Pharma Provides Update on Lacutamab TELLOMAK Trial
6:30am
6-K
EX-99.2
k38314r4f0r0
6 Dec 19
Current report (foreign)
4:20pm
424B4
a7lrl 3bpimwgonm713
18 Oct 19
Prospectus supplement with pricing info
4:08pm
FWP
662o5oc rnqr96g
17 Oct 19
Free writing prospectus
6:07am
F-1/A
vn39f bm4puck5
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1/A
EX-1.1
gmbwl1np2834hn
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1
EX-3.1
8ipnh
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.4
rl0kb25nns0r
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.2
07y7ynww05z
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
zohh1pi6lnc q3i0
20 Sep 19
Registration statement (foreign)
4:08pm